Research

SpotitEarly advances cancer detection through its innovation pipeline, combining AI, automation, and VOC biomarker research. Enhanced data collection improves predictive accuracy and automation scales testing capacity. Together, these breakthroughs pave the way for a more accurate, accessible, and scalable future in early diagnosis.

The cancer detection industry is undergoing rapid transformation, driven by demand for earlier diagnosis, multi-cancer technologies, and AI integration. This article explores the trends shaping the field, from liquid biopsy development to accessibility challenges, and highlights how SpotitEarly addresses these gaps. With a bio-AI breath test platform detecting VOCs at early stages, SpotitEarly combines accuracy, accessibility, and transparency to help lead the cancer detectio

Cancer screening today is effective but limited, with most cancers lacking recommended tests. This article compares traditional methods like mammography and colonoscopy with new liquid biopsy approaches and introduces SpotitEarly’s breath-based test. By detecting volatile organic compounds (VOCs) through a bio-hybrid platform that combines canine olfaction with AI, SpotitEarly is advancing a non-invasive, accurate solution that complements current screening and expands early

The recent Rainbow clinical study, published in Nature Scientific Reports, showcases SpotitEarly’s extraordinary success. It shows SpotitEarly is able to detect cancer at early stages with sensitivity rates exceeding 90% for multiple cancers, including those with no standard screening options available today. This breakthrough positions SpotitEarly as a world leader in early disease detection technology.

Artificial intelligence is at the core of SpotitEarly’s bio-hybrid AI platform, refining and validating results from canine scent detection to ensure accuracy and scalability. This article explores how AI models process complex data, integrate it with clinical workflows, and evolve it over time. By combining canine’s abilities with cutting-edge machine learning, SpotitEarly aims to make early cancer screening more precise, accessible, and widely adopted.

Dogs possess an extraordinary sense of smell — capable of detecting volatile organic compounds linked to cancer at concentrations humans cannot perceive. This article will explain the biology of canine olfaction, the research behind scent-based cancer detection, and how SpotitEarly plans to train dogs as part of a hybrid platform with AI to make early, non-invasive cancer screening possible on a global scale.

At the heart of SpotitEarly’s innovation are its partnerships with leading hospitals and research institutions worldwide. This post explains how these clinical collaborations validate the accuracy of its breath-based screening method, integrate with existing protocols, and enhance early cancer detection efforts. Learn how SpotitEarly’s platform works alongside—not against—current standards for better, non-invasive diagnostics.